Drug Target (Or Biomarker) DUBR (LINC0883) (G344595)

Target Name: DUBR

NCBI ID: G344595

DUBR

Drug Target (Or Biomarker) DUBR (LINC0883)

The identification and development of potential drug targets is a critical aspect of drug discovery and development. A drug target is a protein or a small molecule that is of interest to the drug researcher as it is involved in the disease process and can be targeted to modulate the disease progression. One of the promising drug targets in the recent years is DUBR (LINC0883), which is a gene that has been identified and is involved in the development of various diseases, including cancer.

DUBR (LINC0883) is a gene that encodes a protein known as doublecortin (DcN-terminal) alpha-helical domain binding protein-2 (DcN-alpha-helical domain binding protein-2). This protein plays a crucial role in the development and progression of various diseases, including cancer.

TheDCN-伪-helical domain-binding protein-2 (DcN-伪-helical domain-binding protein-2) gene is a member of the DCN family, which is characterized by the presence of a doublecortin (DcN) domain and an alpha- helix domain binding protein-2 (伪-HSP2) domain. The DcN domain is known to play a crucial role in the regulation of protein stability, localization, and interactions, while the alpha-HSP2 domain is involved in the regulation of protein dynamics and interactions.

The DUBR gene has been identified in various organisms, including humans, and is expressed in various tissues and organs, including the brain, spinal cord, heart, and gastrointestinal tract. The DUBR gene has also been implicated in the development and progression of various diseases, including cancer.

One of the most significant findings related to DUBR gene is its involvement in the development of cancer. Several studies have shown that the expression of DUBR gene is significantly increased in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, these studies have also shown that the DUBR gene is involved in the regulation of cell proliferation and survival, which are crucial aspects of cancer development.

Another finding related to DUBR gene is its involvement in the development of neurodegenerative diseases. Several studies have shown that the expression of DUBR gene is significantly increased in various types of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, these studies have also shown that the DUBR gene is involved in the regulation of neurotransmitter signaling and neuroprotection, which are crucial aspects of neurodegenerative diseases.

DUBR gene has also been implicated in the development of autoimmune diseases. Several studies have shown that the expression of DUBR gene is significantly increased in various types of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. Additionally, these studies have also shown that the DUBR gene is involved in the regulation of immune response and inflammation, which are crucial aspects of autoimmune diseases.

In conclusion, DUBR gene is a promising drug target for the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The identification and development of DUBR gene as a drug target may lead to the development of new treatments for these diseases, which can improve the quality of life for patients. Therefore, further research is needed to fully understand the role of DUBR gene in the development and progression of these diseases.

Protein Name: DPPA2 Upstream Binding RNA

The "DUBR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DUBR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets